in vivo cell therapy

News

J&J takes $2.58bn option to buy in vivo CAR-T firm Sail

Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.

News

Moderna shows in vivo CAR-T hand in R&D update

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

News

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.

News

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

News

Kelonia's in vivo CAR-T data will feature at ASH

Kelonia only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but will report impressive results at ASH next month.

J&J takes $2.58bn option to buy in vivo CAR-T firm Sail

Moderna shows in vivo CAR-T hand in R&D update

ASCO26: In vivo CAR-Ts in the spotlight

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

Kelonia's in vivo CAR-T data will feature at ASH

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

in vivo cell therapy

Editor's Picks